VERU INC.
VERUNext catalyst
Enobosarm
Muscle Loss
Get an email about VERU's next catalysts
Track VERU (VERU) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
VERU Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.34 | FQ end Sep/2026 | Call: tbd
Enobosarm Phase 2 Est. Readout (PLATEAU)
Primary completion for Enobosarm trial (NCT07446998) in Obesity & Overweight
SourceMarket Overview
Stock performance and key metrics
Frequently asked questions
What is in VERU INC.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in VERU INC.'s (VERU) pipeline across Phase 3, Phase 2. Its lead program is Veru-111 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is VERU INC.'s next FDA catalyst?→
VERU INC.'s (VERU) next tracked catalyst is a Phase 2 readout expected October 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VERU biotech catalysts?→
Add VERU to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow VERU INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.